Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
22.70
USDSponsored
+0.87
+3.98%
Feb 20, 15:59 UTC -5
Closed
After-Market
22.41
-0.29
-1.28%
RARE Earnings Reports
Positive Surprise Ratio
RARE beat 20 of 41 last estimates.
49%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$173.14M
/-$1.62
Implied change from Q4 25 (Revenue/ EPS)
-16.36%
/+25.58%
Implied change from Q1 25 (Revenue/ EPS)
+24.30%
/+3.18%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On Feb 12, 2026, RARE reported earnings of -1.29 USD per share (EPS) for Q4 25, missing the estimate of -1.11 USD, resulting in a -15.82% surprise. Revenue reached 207.00 million, compared to an expected 200.91 million, with a 3.03% difference. The market reacted with a -1.07% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 15 analysts forecast an EPS of -1.62 USD, with revenue projected to reach 173.14 million USD, implying an increase of 25.58% EPS, and decrease of -16.36% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Halozyme Therapeutics, Inc.
Report Date
Feb 17, 2026 For Q4 25
Estimate
$2.24
Actual
-$0.24
Surprise
-110.70%
Krystal Biotech, Inc. Common Stock
Report Date
Feb 17, 2026 For Q4 25
Estimate
$1.43
Actual
$1.70
Surprise
+18.33%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Feb 19, 2026 For Q4 25
Estimate
-$3.16
Actual
-$3.50
Surprise
-10.67%
PTC Therapeutics, Inc.
Report Date
Feb 19, 2026 For Q4 25
Estimate
$0.03
Actual
-$1.67
Surprise
-4460.31%
GRAIL, Inc. Common Stock
Report Date
Feb 19, 2026 For Q4 25
Estimate
-$3.18
Actual
-$2.44
Surprise
+23.33%
Travere Therapeutics, Inc. Common Stock
Report Date
Feb 19, 2026 For Q4 25
Estimate
-$0.04
Actual
$0.03
Surprise
+171.94%
Insmed, Inc.
Report Date
Feb 19, 2026 For Q4 25
Estimate
-$1.12
Actual
-$1.54
Surprise
-36.36%
Guardant Health, Inc. Common Stock
Report Date
Feb 19, 2026 For Q4 25
Estimate
-$0.71
Actual
-$0.50
Surprise
+30.12%
NeoGenomics, Inc.
Report Date
Feb 17, 2026 For Q4 25
Estimate
$0.03
Actual
$0.06
Surprise
+53.45%
Prothena Corporation plc Ordinary Shares
Report Date
Feb 19, 2026 For Q4 25
Estimate
-$0.56
Actual
-$0.44
Surprise
+22.81%
FAQ
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.29, missing estimates by -15.82%, and revenue of $207.00M, 3.03% above expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q4 2025 earnings?
The stock price moved down -1.07%, changed from $24.37 before the earnings release to $24.11 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on 15
analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.62 and revenue of $173.14M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement